NDV-HXP-S

NDV-HXP-S
Packaging for the Brazilian version of NDV-HXP-S, ButanVac
Vaccine description
TargetSARS-CoV-2
Vaccine typeviral vector or inactivated
Clinical data
Trade namesButanVac (Brazil)
COVIVAC (Vietnam)
HXP-GPOVac (Thailand)
Patria (Mexico)
Other namesADAPTCOV
Routes of
administration
Intramuscular,[1] Intranasal

NDV-HXP-S (known as ButanVac[2][3] or ADAPTCOV[4] in Brazil, COVIVAC[5] in Vietnam, HXP-GPOVac[6] in Thailand, Patria[7] in Mexico) is a COVID-19 vaccine candidate developed under the leadership of Peter Palese, Adolfo García-Sastre, and Florian Krammer at the Icahn School of Medicine at Mount Sinai.[8][9]

The name NDV-HXP-S comes from the terms Newcastle disease virus, HexaPro, and spike protein.[8] The stabilization of the S protein of SARS-CoV-2 (HexaPro) was achieved by Jason McLellan from the University of Texas at Austin.[10]

  1. ^ "Study of a Live rNDV Based Vaccine Against COVID-19". ClinicalTrials.gov. United States National Library of Medicine. 4 May 2021. NCT04871737. Retrieved 4 May 2021.
  2. ^ "Butantan vai desenvolver e produzir nova vacina contra a Covid-19; testes clínicos da ButanVac devem começar em abril". butantan.gov.br (in Portuguese). Retrieved 16 December 2021.
  3. ^ Simões E, Fonseca P (26 March 2021). "Brazil posts record 3,650 new COVID-19 deaths, unveils two homegrown vaccines". Reuters. Retrieved 7 April 2021. Earlier, Sao Paulo's Butantan biomedical institute said it will seek approval ... Butantan aims to produce 40 million doses of the Butanvac vaccine ... The vaccine was developed using a modified virus, which causes the Newcastle disease in birds ...
  4. ^ "Clinical Trial of the COVID-19 Vaccine (Recombinant, Inactivated) in Brazil (ADAPTCOV)". clinicaltrials.gov. United States National Library of Medicine. 6 August 2021. Retrieved 6 August 2021.
  5. ^ "A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC". clinicaltrials.gov. United States National Library of Medicine. April 2021. Retrieved 9 April 2021.
  6. ^ "Mahidol-GPO's human trials of its COVID-19 vaccine show promising results". Thai PBS World. 1 July 2021. Retrieved 19 July 2021.
  7. ^ Juarez C (22 April 2021). "Vacuna Patria: esto es lo que se sabe de su avance y eventual producción". The Logistics World. Retrieved 24 June 2021.
  8. ^ a b Zimmer C (5 April 2021). "Researchers Are Hatching a Low-Cost Coronavirus Vaccine". The New York Times. Retrieved 7 April 2021.
  9. ^ Cite error: The named reference sun-et-al-ndv-2020 was invoked but never defined (see the help page).
  10. ^ Cite error: The named reference struc-based-des-nature was invoked but never defined (see the help page).